A 70-year-old man with prostate cancer (adenocarcinoma; pT3aN0Mx; GS: 4 + 4) underwent radical prostatectomy and lymph node dissection in February 2008. In December 2009, biochemical recurrence occurred and prostate-specific antigen progressively increased to 4.63 ng/mL despite local salvage radiotherapy and androgen deprivation. 68 Ga-PSMA PET/CT showed a positive left iliac lymph node and a pathological left pulmonary lesion, which was highly positive in a subsequent 18 F-FDG PET/CT. Lymph node resection confirmed an adenocarcinoma metastasis of the prostate cancer and lung surgery demonstrated a sarcomatoid metastasis of prostate cancer. After surgery, prostate-specific antigen decreased to 0.03 ng/mL.
. Biochemical recurrence in prostate cancer is a common event after radical prostatectomy and/or radiotherapy occurring in up to 40% of cases within 10 years after the initial treatment. 1, 2 In the presented case, prostate-specific antigen (PSA) level continued rising despite local radiotherapy and androgen suppression (PSA level, 4.63 ng/mL) 2 years after primary treatment. A 68 Ga-PSMA PET/CT was performed (MIP image on the left), where a positive left iliac lymph node (arrow) as well as a left heterogeneous PSMA-positive lung mass (arrowhead) were observed. It has been reported that other malignancies or even benign lesions may show a pathologic uptake of PSMA ligands. 3, 4 In this case, due to the localization, single pulmonary appearance and relatively low uptake the pulmonary lesion was suspected to be a secondary primary. After lymph node dissection, the PSA values continuously rised (PSA level, 7.12 ng/mL) and 18 F-FDG PET/CT was performed (MIP image on the right). The lung mass was highly 18 F-FDG positive. No evidence of local recurrence of prostate cancer in both PET/CT scans was found. PET with 68 Ga-PSMA ligand is a promising imaging procedure for prostate cancer. [5] [6] [7] In comparison with choline PET, this radiotracer shows a higher detection rate even at relatively low PSA levels. 8, 9 C, At 3 months after surgical resection of the iliac lymph node metastasis, the remaining 68 Ga-PSMA-positive lung lesion had grown and showed high FDG uptake, which is uncommon in well-differentiated prostate cancer. Therefore, a second lung malignancy was suspected. However, histology confirmed a sarcomatoid, partially undifferentiated, metastasis of prostate carcinoma, a rare entity belonging to the group of nonacinar carcinomas (approximately 5%-10% of all prostate cancer). 10 In the case of our patient, the lesion only showed a moderate elevation of PSA level, but sarcomatoid prostate cancer can even develop without PSA level elevation. In such cases, the detection of disease progression can be difficult. This case report demonstrates that even this rare histologic subtype of prostate cancer can be detected by 68 Ga-PSMA PET. Only approximately 100 cases are reported in the literature. The pathogenesis of this type of prostate cancer is still uncertain, although many of the published cases of sarcomatoid prostate cancer have been associated with a prior history of differentiated prostate adenocarcinoma. Recently, a prostate-specific gene deletion was detected in both the sarcomatoid component and the differentiated adenocarcinoma, confirming the common tumor derivation from prostate epithelium. 11 The most frequent localizations of sarcomatoid metastases are the lung and lymph nodes, and the surgical treatment seems to be the most effective therapeutic approach. 10 After the resection of the lung metastasis, PSA level decreased to less than 0.05 ng/mL. In addition, according to the course of disease of other sarcomatoid malignancies, sarcomatoid prostate cancer is associated with a poor prognosis. 12 It is notable that after resection of the
